Chief executive, NICE ▼2
Sir Andrew Dillon has calmly navigated the National Institute for Health and Clinical Excellence through the challenges of its first decade.
However, six months on from the election, the government’s proposals to reform the drugs approval process have given Sir Andrew a potential new headache. Challenges include the launch of a “cancer drugs fund” which will pay for treatments not approved by NICE. Health minister Earl Howe (19) has also declared the government’s introduction of value based pricing for NHS drugs will make NICE’s current role “somewhat redundant”.
Sir Andrew can at least reassure himself that NICE has been asked to publish new care guidelines that will underpin both regulation and commissioning.